Ventus Therapeutics develops small molecule drugs targeting autoimmune and inflammatory diseases, as well as cancer, utilizing its machine learning-enabled ReSOLVE™ platform to identify novel therapeutic candidates. The company is advancing two lead programs, including a brain-penetrant NLRP3 inhibitor and a first-in-class cGAS inhibitor, through clinical development to address unmet medical needs in these areas.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many autoimmune, inflammatory, and neurological diseases lack effective treatments due to the difficulty in identifying and targeting the key molecular drivers of these conditions. Traditional drug discovery methods often fail to address the complexities of these diseases, resulting in limited therapeutic options for patients.
Solution
Ventus Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary, machine learning-enabled ReSOLVE™ platform to discover and develop novel small molecule therapeutics. The ReSOLVE™ platform facilitates the identification of previously unrecognized drug targets and accelerates the design of selective inhibitors. Ventus is currently advancing two lead programs through clinical trials: VENT-02, a brain-penetrant NLRP3 inhibitor, and VENT-03, a first-in-class cGAS inhibitor, to address unmet needs in immunology, inflammation, and neurology.
Target Audience
The primary target audience includes patients suffering from autoimmune, inflammatory, and neurological diseases, as well as pharmaceutical companies seeking innovative drug candidates in these therapeutic areas.
Features
- ReSOLVE™ platform leveraging machine learning to identify novel therapeutic candidates
- VENT-02: Brain-penetrant NLRP3 inhibitor targeting inflammatory diseases, currently in clinical development
- VENT-03: First-in-class cGAS inhibitor for autoimmune and inflammatory disorders such as lupus, currently in clinical development
- Focus on small molecule drugs for immunology, inflammation, and neurology
- Pipeline of novel medicines designed to address previously undruggable targets